Halper Sadeh Investigates Lisata Therapeutics–Kuva Deal Over Non‑Tradeable CVR Structure
- Halper Sadeh is investigating the Lisata–Kuva deal offering $4 cash plus two non‑tradeable CVRs.
- The firm says CVRs may restrict liquidity, obscure true value, and potentially violate duties or securities laws.
- It may seek higher consideration, additional disclosures, or other relief, pressuring Lisata and Kuva to renegotiate.
Lisata–Kuva deal draws legal scrutiny over contingent‑value structure
Investor‑rights firm Halper Sadeh LLC is investigating Lisata Therapeutics’ proposed sale to Kuva Labs after shareholders are offered $4.00 per share in cash plus two non‑tradeable contingent value rights (CVRs). The New York firm says it is probing whether the deal’s structure and related protections violate federal securities laws or breach directors’ fiduciary duties by conferring outsized benefits on insiders or by including terms that limit superior competing offers.
Halper Sadeh flags specific concerns about the non‑tradeable CVRs, noting they restrict liquidity and may obscure the true value being offered to ordinary shareholders compared with insiders or counterparties. The firm also highlights deal protections—such as covenants or no‑shop provisions—that can deter competing bids and potentially lock in consideration that undervalues Lisata’s assets or pipeline. It says, on behalf of shareholders, it may seek increased consideration, additional disclosures and other relief.
The inquiry underscores a broader tension in biotech mergers, where acquirers use CVRs and contingent payments to bridge valuation gaps on development risk. Such mechanisms, while common, can invite legal challenges if boards do not adequately justify the terms or fully disclose potential outcomes. Halper Sadeh’s contingent‑fee model and public solicitation of shareholders may pressure Lisata and Kuva to renegotiate terms or expand disclosures to reduce litigation risk and preserve deal certainty.
Other transactions named in the probe
Halper Sadeh is concurrently reviewing several other proposed transactions, including RAPT Therapeutics’ sale to GSK for $58.00 per share, Allegiant Travel Company’s merger with Sun Country Airlines in which Allegiant shareholders would hold roughly 67% of the combined company, and Mission Produce’s merger with Calavo Growers where Mission shareholders are expected to own about 80.3% post‑closing.
Firm profile and shareholder outreach
The firm says it represents investors worldwide and often pursues remedies on a contingent‑fee basis so clients incur no out‑of‑pocket legal costs. Halper Sadeh states its attorneys have secured corporate reforms and recoveries in prior matters, while noting that past results do not guarantee future outcomes. It invites affected Lisata shareholders to contact the firm promptly for an evaluation of potential claims.